OBX

Obsidian Therapeutics, Inc.

Price Chart

Latest Quote

$34.00

+6.70 (+24.54%)

Current Price

Previous Close	$27.30
Open	$49.97
Day High	$49.97
Day Low	$25.02
Volume	12,576

Fetched: 2026-08-05T04:00:22

Stock Information

Shares Outstanding	61.73M
Sector	Healthcare
Industry	Biotechnology
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Financial Ratios

Returns & Margins

Ownership

Insider & Institutional transactions data not available

Valuation Ratios

Analyst Data

Recommendation

none

Technical Indicators

Performance History

YTD

+0.00%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-08-04	$34.00	12,576

About Obsidian Therapeutics, Inc.

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform designed to regulate protein function using FDA-approved small-molecule drugs and is advancing tumor-infiltrating lymphocyte (TIL) cell therapies that leverage mbIL15 to enhance persistence, antitumor activity, and clinical safety. Access to investigational therapies is currently limited to participation in clinical trials, and the company collaborates with other organizations to apply its platform technology. The company was founded in 2015 and is based in Cambridge, Massachusetts.

📰 Latest News

No news articles available at the moment. Check back later for updates on OBX.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31
Revenue
Total Revenue	$0	$0
Operating Revenue	$0	$0
Expenses
Total Expenses	$105,667,000	$91,255,000
Net Non Operating Interest Income Expense	$5,060,000	$8,146,000
Operating Expense	$105,667,000	$91,255,000
General And Administrative Expense	$19,554,000	$18,068,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-100,607,000	$-83,109,000
Net Interest Income	$5,060,000	$8,146,000
Interest Income	$5,060,000	$8,146,000
Normalized Income	$-100,607,000	$-83,109,000
Net Income From Continuing And Discontinued Operation	$-100,607,000	$-83,109,000
Total Operating Income As Reported	$-105,667,000	$-91,255,000
Net Income Common Stockholders	$-100,607,000	$-83,109,000
Net Income	$-100,607,000	$-83,109,000
Net Income Including Noncontrolling Interests	$-100,607,000	$-83,109,000
Net Income Continuous Operations	$-100,607,000	$-83,109,000
Pretax Income	$-100,607,000	$-83,109,000
Interest Income Non Operating	$5,060,000	$8,146,000
Operating Income	$-105,667,000	$-91,255,000
Other
Tax Effect Of Unusual Items	$0	$0
Tax Rate For Calcs	$0	$0
Normalized EBITDA (Bullshit earnings)	$-104,183,000	$-89,728,000
Reconciled Depreciation	$1,484,000	$1,527,000
EBITDA (Bullshit earnings)	$-104,183,000	$-89,728,000
EBIT	$-105,667,000	$-91,255,000
Diluted NI Availto Com Stockholders	$-100,607,000	$-83,109,000
Tax Provision	$0	$0
Research And Development	$86,113,000	$73,187,000
Selling General And Administration	$19,554,000	$18,068,000
Other Gand A	$19,554,000	$18,068,000

Fetched: 2026-08-05

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31
Assets
Net Tangible Assets	$-266,037,000	$-174,431,000
Total Assets	$88,580,000	$183,713,000
Total Non Current Assets	$7,064,000	$10,865,000
Other Non Current Assets	$1,004,000	$1,004,000
Current Assets	$81,516,000	$172,848,000
Other Current Assets	$1,030,000	$4,578,000
Cash Cash Equivalents And Short Term Investments	$80,486,000	$168,270,000
Cash And Cash Equivalents	$40,405,000	$49,761,000
Debt
Total Debt	$4,283,000	$6,814,000
Long Term Debt And Capital Lease Obligation	$1,224,000	$3,824,000
Current Debt And Capital Lease Obligation	$3,059,000	$2,990,000
Liabilities
Total Liabilities Net Minority Interest	$354,617,000	$358,144,000
Total Non Current Liabilities Net Minority Interest	$339,255,000	$342,058,000
Other Non Current Liabilities	$3,000	$206,000
Current Liabilities	$15,362,000	$16,086,000
Other Current Liabilities	$1,415,000	$979,000
Payables And Accrued Expenses	$7,058,000	$6,557,000
Payables	$12,000	$1,818,000
Accounts Payable	$12,000	$1,818,000
Equity
Common Stock Equity	$-266,037,000	$-174,431,000
Total Equity Gross Minority Interest	$-266,037,000	$-174,431,000
Stockholders Equity	$-266,037,000	$-174,431,000
Gains Losses Not Affecting Retained Earnings	$23,000	$-27,000
Other Equity Adjustments	$23,000	$-27,000
Retained Earnings	$-295,935,000	$-195,328,000
Preferred Securities Outside Stock Equity	$338,028,000	$338,028,000
Other
Tangible Book Value	$-266,037,000	$-174,431,000
Invested Capital	$-266,037,000	$-174,431,000
Working Capital	$66,154,000	$156,762,000
Capital Lease Obligations	$4,283,000	$6,814,000
Total Capitalization	$-266,037,000	$-174,431,000
Additional Paid In Capital	$29,874,000	$20,923,000
Capital Stock	$1,000	$1,000
Common Stock	$1,000	$1,000
Long Term Capital Lease Obligation	$1,224,000	$3,824,000
Current Capital Lease Obligation	$3,059,000	$2,990,000
Pensionand Other Post Retirement Benefit Plans Current	$3,830,000	$5,560,000
Current Accrued Expenses	$7,046,000	$4,739,000
Net PPE	$6,060,000	$9,861,000
Accumulated Depreciation	$-9,510,000	$-8,026,000
Gross PPE	$15,570,000	$17,887,000
Leases	$261,000	$261,000
Other Properties	$14,166,000	$16,483,000
Machinery Furniture Equipment	$1,143,000	$1,143,000
Properties	$0	$0
Other Short Term Investments	$40,081,000	$118,509,000

Fetched: 2026-08-05

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31
Free Cash Flow
Free Cash Flow	$-90,466,000	$-75,781,000
Operating Activities
Operating Cash Flow	$-90,393,000	$-75,002,000
Cash Flow From Continuing Operating Activities	$-90,393,000	$-75,002,000
Operating Gains Losses	$-3,000	$-8,000
Investing Activities
Capital Expenditure	$-73,000	$-779,000
Investing Cash Flow	$81,017,000	$-53,874,000
Cash Flow From Continuing Investing Activities	$81,017,000	$-53,874,000
Financing Activities
Issuance Of Capital Stock	$0	$160,500,000
Financing Cash Flow	$20,000	$162,515,000
Cash Flow From Continuing Financing Activities	$20,000	$162,515,000
Net Preferred Stock Issuance	$0	$160,500,000
Preferred Stock Issuance	$0	$160,500,000
Net Other Financing Charges	-	$-532,000
Other
End Cash Position	$41,409,000	$50,765,000
Beginning Cash Position	$50,765,000	$17,126,000
Changes In Cash	$-9,356,000	$33,639,000
Proceeds From Stock Option Exercised	$20,000	$2,547,000
Net Investment Purchase And Sale	$81,090,000	$-53,095,000
Sale Of Investment	$162,000,000	$78,000,000
Purchase Of Investment	$-80,910,000	$-131,095,000
Net PPE Purchase And Sale	$-73,000	$-779,000
Purchase Of PPE	$-73,000	$-779,000
Change In Working Capital	$2,555,000	$1,752,000
Change In Other Current Liabilities	$-200,000	$200,000
Change In Payables And Accrued Expense	$-793,000	$4,285,000
Change In Accrued Expense	$1,013,000	$3,584,000
Change In Payable	$-1,806,000	$701,000
Change In Account Payable	$-1,806,000	$701,000
Change In Prepaid Assets	$3,548,000	$-2,733,000
Other Non Cash Items	$-141,000	$-17,000
Stock Based Compensation	$8,931,000	$7,060,000
Amortization Of Securities	$-2,612,000	$-2,207,000
Depreciation Amortization Depletion	$1,484,000	$1,527,000
Depreciation And Amortization	$1,484,000	$1,527,000
Depreciation	$1,484,000	$1,527,000
Gain Loss On Investment Securities	$-3,000	$-8,000
Net Income From Continuing Operations	$-100,607,000	$-83,109,000

Fetched: 2026-08-05